Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
acute myeloid leukemia (AML)
Biotech
Sellas’ AML asset tied to 50% response rate in certain patients
Sellas’ investigational CDK9 inhibitor has scored in a midstage AML study, demonstrating an ORR of more than double the 20% goal.
Gabrielle Masson
Jul 15, 2025 10:34am
Vor Bio to wind down, laying off most staff
May 8, 2025 10:50am
Orca prepares to make market plunge after phase 3 win
Mar 17, 2025 7:00am
Ryvu loses 30% of staff in focus on ph. 3 blood cancer trials
Feb 25, 2025 10:00am
Apollomics, after giving up on leukemia drug, posts ph. 3 fail
Dec 20, 2024 9:30am
Foghorn drops sole wholly owned clinical asset after AML failure
Dec 16, 2024 7:48am
